Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat

Sponsor
University of Miami
Study ID
NCT02920190
Phase
PHASE4
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    1.8 mg Liraglutide administered subcutaneously once daily for 12 consecutive months

Study Details

The purpose of this research study is to learn about the effect of Liraglutide (Victoza) on the fat of the heart and some fat cells in blood.

Key Dates

Start date
Sep 1, 2020
Status verified
Sep 2020
Primary completion
Sep 1, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide Group
    Participants in this group will receive the Liraglutide intervention for 12 months

Primary Outcome Measure

Change in Epicardial Fat Thickness [ Time Frame: Baseline, 12 months ]

Related Studies